Daily Cardiology Research Analysis
Three papers stand out today: a network meta-analysis that challenges the long-standing superiority of ticagrelor over clopidogrel in ACS DAPT; a randomized-trial meta-analysis indicating clopidogrel monotherapy reduces MACE versus aspirin without higher bleeding; and an AI foundation model (ScarNet) that markedly improves automated LGE scar quantification in CMR. Together, they inform antiplatelet selection and advance imaging precision.
Summary
Three papers stand out today: a network meta-analysis that challenges the long-standing superiority of ticagrelor over clopidogrel in ACS DAPT; a randomized-trial meta-analysis indicating clopidogrel monotherapy reduces MACE versus aspirin without higher bleeding; and an AI foundation model (ScarNet) that markedly improves automated LGE scar quantification in CMR. Together, they inform antiplatelet selection and advance imaging precision.
Research Themes
- Reappraisal of antiplatelet therapy in ACS and chronic ASCVD
- AI-driven cardiac MRI scar quantification and risk stratification
- Methodological rigor and sensitivity analyses shaping clinical guidance
Selected Articles
1. Ticagrelor Paradox: Systematic Review and Network Meta-Analysis.
In a network meta-analysis of 12 RCTs (n=52,415), the inclusion of PLATO drove much of ticagrelor’s observed benefit over clopidogrel in ACS DAPT; when PLATO was excluded, advantages attenuated. Both ticagrelor and prasugrel were associated with higher bleeding across analyses.
Impact: This work rigorously tests the sensitivity of ticagrelor’s benefit to a single pivotal trial, challenging a current therapeutic paradigm in ACS.
Clinical Implications: Antiplatelet selection in ACS should consider the uncertainty introduced by PLATO; individualized choices weighing ischemic versus bleeding risk (and pragmatic head-to-head evidence) are warranted rather than assuming ticagrelor’s superiority.
Key Findings
- Included 12 RCTs with 52,415 patients comparing DAPT regimens (aspirin+clopidogrel/prasugrel/ticagrelor).
- With PLATO included, ticagrelor vs clopidogrel showed lower cardiovascular mortality (HR 0.83; 95% CI 0.72–0.96); without PLATO, HR 0.96 (95% CI 0.73–1.25).
- Ticagrelor and prasugrel were consistently associated with higher major and overall bleeding in analyses with and without PLATO.
Methodological Strengths
- Network meta-analysis restricted to randomized trials with explicit PLATO-inclusion sensitivity analyses.
- Comprehensive evaluation of ischemic and bleeding endpoints with comparative estimates across regimens.
Limitations
- Relies on study-level data and network meta-analytic assumptions (transitivity/consistency).
- PLATO’s trial-specific context cannot be fully decomposed; patient-level modifiers (e.g., adherence, regional practice) not assessed.
Future Directions: Pragmatic, adequately powered head-to-head RCTs and individual patient data meta-analyses are needed to refine antiplatelet selection in diverse ACS populations.
BACKGROUND: Based on the landmark PLATO (Platelet Inhibition and Patient Outcomes) and TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction) trials, current guidelines recommend ticagrelor and prasugrel over clopidogrel for acute coronary syndrome. However, subsequent studies have failed to replicate the reported benefits of ticagrelor, raising concerns about the validity of the PLATO trial's findings. METHODS: Randomized trials published until January 2025 were searched on PubMed and Embase and included if they compared 2 of the 3 standard dual antiplatelet therapies: 12 months aspirin plus clopidogrel, prasugrel, or ticagrelor. We constructed a network with and without PLATO to assess its impact on the synthesized risk estimates on major adverse cardiovascular events, patient mortality, myocardial infarction, and stent thrombosis, as well as major bleeding and major or minor bleeding. RESULTS: Twelve trials, enrolling 52 415 patients (clopidogrel: 23 557; ticagrelor: 13 344, prasugrel: 15 514) were included. The analysis with PLATO showed lower hazard ratios for ticagrelor versus clopidogrel than the analysis without PLATO in major adverse cardiovascular events, mortality, myocardial infarction, and bleeding outcomes (e.g., cardiovascular mortality; hazard ratio [HR], 0.83 [95% CI, 0.72-0.96] when PLATO was included; HR, 0.96 [95% CI, 0.73-1.25] when PLATO was excluded). Ticagrelor and prasugrel were associated with higher incidences of major bleeding and major or minor bleeding for analyses including and excluding PLATO, altohugh the point estimates for ticagrelor were lower when PLATO was included. CONCLUSIONS: The pooled estimates with PLATO favored ticagrelor compared with estimates without PLATO in several studied outcomes, potentially suggesting the substantial impacts of PLATO's findings on the pooled risk estimates; therefore, additional evidence may be needed given the large number of patients worldwide treated with dual antiplatelet therapy.
2. Antiplatelet therapy with clopidogrel versus aspirin in atherosclerotic cardiovascular disease: a systematic review and meta-analysis.
Across six randomized trials (n=33,508), clopidogrel monotherapy reduced MACE versus aspirin (OR 0.85) without increasing total or severe bleeding. Findings support clopidogrel as a potentially preferable SAPT option in ASCVD.
Impact: Head-to-head randomized evidence synthesis indicates a clinically meaningful advantage of clopidogrel monotherapy, with no bleeding penalty.
Clinical Implications: For secondary prevention in ASCVD, clopidogrel monotherapy may be favored over aspirin, particularly where CYP2C19 loss-of-function prevalence is low or genotype-guided strategies are available.
Key Findings
- Six RCTs totaling 33,508 patients compared clopidogrel vs aspirin as SAPT in ASCVD.
- Clopidogrel significantly reduced MACE (OR 0.85; 95% CI 0.77–0.94; p<0.001).
- No increase in total or severe bleeding was observed with clopidogrel compared with aspirin.
Methodological Strengths
- Restriction to randomized controlled trials with predefined primary and secondary endpoints.
- Use of random-effects models to accommodate between-study heterogeneity.
Limitations
- Heterogeneity in trial eras, populations, and concomitant therapies may influence pooled estimates.
- Did not incorporate pharmacogenomic modifiers (e.g., CYP2C19) at the patient level.
Future Directions: Prospective genotype-guided trials and cost-effectiveness analyses comparing clopidogrel vs aspirin monotherapy across diverse populations.
BACKGROUND AND AIMS: Whether single antiplatelet therapy (SAPT) with clopidogrel offers superior ischemic efficacy and a more favourable bleeding profile than aspirin in atherosclerotic cardiovascular disease is unclear. METHODS: A systematic search on the main databases Medline, Web of Science, and Embase until April 21, 2024 was performed. Only randomized trials were eligible for this analysis. As primary endpoint we analyzed major adverse cardiovascular events (MACE), defined as a composite of all-cause mortality, non-fatal myocardial infarction (MI) and non-fatal stroke. As secondary endpoints we investigated the individual primary endpoints as well as the rate of total and severe bleeding events. The analysis was carried out using the odds ratio (OR) as outcome measure. Due to the expected heterogeneity across studies, a random-effects model was fitted to the data. RESULTS: In total, 6 randomized trials comprising 33,508 patients (16,824 on clopidogrel, 16,684 on aspirin) were analyzed. Clopidogrel as compared to aspirin significantly reduced MACE (OR 0.85 [95 %CI 0.77-0.94], p < 0.001, I CONCLUSION: In patients with atherosclerotic cardiovascular disease, SAPT with clopidogrel is associated with lower MACE rates as compared to aspirin without increasing the risk of bleeding.
3. ScarNet: a novel foundation model for automated myocardial scar quantification from late gadolinium-enhancement images.
ScarNet, combining a fine-tuned MedSAM encoder and UNet-based decoder, achieved expert-level LGE scar segmentation (median DICE 0.912; volume CCC 0.995) and robustness to noise, outperforming nnU-Net and MedSAM on 184 independent test patients.
Impact: Provides a scalable, high-accuracy foundation model to standardize LGE scar quantification, reducing manual burden and variability that currently impede routine clinical use.
Clinical Implications: Automated, reproducible LGE scar quantification could enable broader MACE risk stratification, streamline reporting, and support therapy planning (e.g., ablation, ICD decisions) once externally validated and integrated into workflows.
Key Findings
- On 184 test patients, ScarNet achieved median DICE 0.912 (IQR 0.863–0.944) and CCC 0.963 for scar boundaries.
- Scar volume quantification showed CCC 0.995 with −0.63% bias and 4.3% CoV versus manual analysis.
- Outperformed nnU-Net (DICE 0.638; CCC 0.734) and MedSAM (DICE 0.046; CCC 0.018); demonstrated higher sensitivity (95.3%) and specificity (92.3%).
Methodological Strengths
- Large annotated dataset with dedicated train/validation/test splits and ablation studies.
- Monte Carlo noise perturbation analyses demonstrating robustness; direct comparisons to state-of-the-art baselines.
Limitations
- Evaluated predominantly in ischemic cardiomyopathy; generalizability to non-ischemic phenotypes and multi-center scanners remains to be shown.
- No prospective clinical outcome validation linking automated metrics to patient events.
Future Directions: External multi-center validation, regulatory-grade benchmarking, and prospective studies assessing impact on decision-making and MACE prediction.
BACKGROUND: Late gadolinium enhancement (LGE) imaging remains the gold standard for assessing myocardial fibrosis and scarring, with left ventricular (LV) LGE presence and extent serving as a predictor of major adverse cardiac events (MACE). Despite its clinical significance, LGE-based LV scar quantification is not used routinely due to the labor-intensive manual segmentation and substantial inter-observer variability. METHODS: We developed ScarNet that synergistically combines a transformer-based encoder in medical segment anything model (MedSAM), which we fine-tuned with our dataset, and a convolution-based decoder in UNet with tailored attention blocks to automatically segment myocardial scar boundaries while maintaining anatomical context. This network was trained and fine-tuned on an existing database of 401 ischemic cardiomyopathy patients (4137 2D LGE images) with expert segmentation of myocardial and scar boundaries in LGE images, validated on 100 patients (1034 2D LGE images) during training, and tested on unseen set of 184 patients (1895 2D LGE images). Ablation studies were conducted to validate each architectural component's contribution. RESULTS: In 184 independent testing patients, ScarNet achieved accurate scar boundary segmentation (median DICE=0.912 [interquartile range (IQR): 0.863-0.944], concordance correlation coefficient [CCC]=0.963), significantly outperforming both MedSAM (median DICE=0.046 [IQR: 0.043-0.047], CCC=0.018) and nnU-Net (median DICE=0.638 [IQR: 0.604-0.661], CCC=0.734). For scar volume quantification, ScarNet demonstrated excellent agreement with manual analysis (CCC=0.995, percent bias=-0.63%, CoV=4.3%) compared to MedSAM (CCC=0.002, percent bias=-13.31%, CoV=130.3%) and nnU-Net (CCC=0.910, percent bias=-2.46%, CoV=20.3%). Similar trends were observed in the Monte Carlo simulations with noise perturbations. The overall accuracy was highest for ScarNet (sensitivity=95.3% (163/171); specificity=92.3% (12/13)), followed by nnU-Net (sensitivity=74.9% (128/171); specificity=69.2% (9/13)) and MedSAM (sensitivity=15.2% (26/171); specificity=92.3% (12/13)). CONCLUSION: ScarNet outperformed MedSAM and nnU-Net for predicting myocardial and scar boundaries in LGE images of patients with ischemic cardiomyopathy. The Monte Carlo simulations demonstrated that ScarNet is less sensitive to noise perturbations than other tested networks.